BR112018073794A2 - segmento genômico, cdna, vetor, célula hospedeira, partícula, método de produção de um segmento genômico, método de geração da partícula, vacina, composição farmacêutica - Google Patents
segmento genômico, cdna, vetor, célula hospedeira, partícula, método de produção de um segmento genômico, método de geração da partícula, vacina, composição farmacêuticaInfo
- Publication number
- BR112018073794A2 BR112018073794A2 BR112018073794-1A BR112018073794A BR112018073794A2 BR 112018073794 A2 BR112018073794 A2 BR 112018073794A2 BR 112018073794 A BR112018073794 A BR 112018073794A BR 112018073794 A2 BR112018073794 A2 BR 112018073794A2
- Authority
- BR
- Brazil
- Prior art keywords
- genomic segment
- particle
- segment
- pichinde virus
- vaccine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/06—Quantitative determination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10051—Methods of production or purification of viral material
- C12N2760/10052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662338400P | 2016-05-18 | 2016-05-18 | |
| US62/338,400 | 2016-05-18 | ||
| PCT/EP2017/061865 WO2017198726A1 (en) | 2016-05-18 | 2017-05-17 | Tri-segmented pichinde viruses as vaccine vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018073794A2 true BR112018073794A2 (pt) | 2019-02-26 |
Family
ID=58800799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018073794-1A BR112018073794A2 (pt) | 2016-05-18 | 2017-05-17 | segmento genômico, cdna, vetor, célula hospedeira, partícula, método de produção de um segmento genômico, método de geração da partícula, vacina, composição farmacêutica |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20190135875A1 (enExample) |
| EP (1) | EP3458593A1 (enExample) |
| JP (3) | JP7254018B2 (enExample) |
| KR (2) | KR102671785B1 (enExample) |
| CN (2) | CN117486979A (enExample) |
| AU (2) | AU2017266738B2 (enExample) |
| BR (1) | BR112018073794A2 (enExample) |
| CA (1) | CA3023599A1 (enExample) |
| EA (1) | EA201892648A1 (enExample) |
| IL (2) | IL262963B2 (enExample) |
| MX (2) | MX2018013956A (enExample) |
| NZ (2) | NZ788311A (enExample) |
| SG (1) | SG11201810048VA (enExample) |
| WO (1) | WO2017198726A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4186978A1 (en) | 2007-12-27 | 2023-05-31 | Universität Zürich | Replication-defective arenavirus vectors |
| HRP20211015T1 (hr) | 2013-12-03 | 2021-10-01 | Hookipa Biotech Gmbh | Cjepivo protiv citomegalovirusa (cmv) |
| US10722564B2 (en) | 2014-11-13 | 2020-07-28 | Université de Genéve | Tri-segmented arenaviruses as vaccine vectors |
| CN107921117B (zh) | 2015-06-10 | 2022-06-07 | 霍欧奇帕生物科技有限公司 | Hpv疫苗 |
| US11214598B2 (en) | 2015-11-04 | 2022-01-04 | Hookipa Biotech Gmbh | Vaccines against hepatitis B virus |
| EP3960197A1 (en) | 2015-11-12 | 2022-03-02 | Hookipa Biotech GmbH | Arenavirus particles as cancer vaccines |
| CN110719788A (zh) * | 2017-04-07 | 2020-01-21 | 霍欧奇帕生物科技有限公司 | 治疗实体瘤的沙粒病毒颗粒 |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| PE20220231A1 (es) | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso |
| EP3999107A1 (en) | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| EP4458975A3 (en) | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| EP4055173A1 (en) | 2019-11-07 | 2022-09-14 | Universität Basel Vizerektorat Forschung | Arenaviruses as vectors |
| EP4069729B1 (en) | 2019-12-06 | 2025-01-22 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| EP4157342A1 (en) | 2020-05-29 | 2023-04-05 | Hookipa Biotech GmbH | Cancer treatment strategies using arenavirus vectors |
| US12053517B2 (en) | 2021-01-14 | 2024-08-06 | Gilead Sciences, Inc. | HIV vaccines and methods of using |
| BR112023019365A2 (pt) | 2021-03-23 | 2023-12-26 | Hookipa Biotech Gmbh | Segmento s de arenavírus, cdna, vetor de expressão de dna, célula hospedeira, partícula de arenavírus trissegmentada, método para gerar uma partícula de arenavírus trissegmentada, composição farmacêutica, método para tratar câncer de próstata e kit |
| WO2022238546A1 (en) | 2021-05-13 | 2022-11-17 | Hookipa Biotech Gmbh | Arenaviruses as vectors |
| AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| WO2022269362A2 (en) * | 2021-06-21 | 2022-12-29 | Vaxxinova International B.V. | Veterinary viral vector |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| EP4429698A1 (en) * | 2021-11-08 | 2024-09-18 | Hookipa Biotech GmbH | Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies |
| WO2023152116A1 (en) | 2022-02-08 | 2023-08-17 | Hookipa Biotech Gmbh | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
| CN119677546A (zh) | 2022-07-12 | 2025-03-21 | 吉利德科学公司 | Hiv免疫原性多肽和疫苗及其用途 |
| WO2025191169A1 (en) | 2024-03-15 | 2025-09-18 | Hookipa Biotech Gmbh | Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| EP2007765B1 (en) | 2006-03-23 | 2012-06-27 | Novartis AG | Immunopotentiating compounds |
| CA2646539A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| EP4186978A1 (en) * | 2007-12-27 | 2023-05-31 | Universität Zürich | Replication-defective arenavirus vectors |
| EP2968506B1 (en) * | 2013-03-15 | 2019-07-31 | Université de Genève | Anti-mycobacterial vaccines |
| CN103224999B (zh) * | 2013-04-25 | 2015-11-18 | 中华人民共和国大榭出入境检验检疫局 | 检测沙粒病毒科病毒的简并引物及rt-pcr检测方法 |
| AU2015321557B2 (en) | 2014-09-22 | 2020-05-14 | Regents Of The University Of Minnesota | Pichinde virus reverse genetics system and methods of use |
-
2017
- 2017-05-17 CN CN202311410316.3A patent/CN117486979A/zh active Pending
- 2017-05-17 NZ NZ788311A patent/NZ788311A/en unknown
- 2017-05-17 KR KR1020187036105A patent/KR102671785B1/ko active Active
- 2017-05-17 IL IL262963A patent/IL262963B2/en unknown
- 2017-05-17 BR BR112018073794-1A patent/BR112018073794A2/pt active Search and Examination
- 2017-05-17 US US16/302,086 patent/US20190135875A1/en not_active Abandoned
- 2017-05-17 EA EA201892648A patent/EA201892648A1/ru unknown
- 2017-05-17 EP EP17726575.8A patent/EP3458593A1/en active Pending
- 2017-05-17 KR KR1020247018106A patent/KR20240095333A/ko active Pending
- 2017-05-17 CN CN201780044797.7A patent/CN109804074B/zh active Active
- 2017-05-17 AU AU2017266738A patent/AU2017266738B2/en active Active
- 2017-05-17 SG SG11201810048VA patent/SG11201810048VA/en unknown
- 2017-05-17 MX MX2018013956A patent/MX2018013956A/es unknown
- 2017-05-17 CA CA3023599A patent/CA3023599A1/en active Pending
- 2017-05-17 NZ NZ748120A patent/NZ748120A/en unknown
- 2017-05-17 JP JP2019513483A patent/JP7254018B2/ja active Active
- 2017-05-17 IL IL314272A patent/IL314272A/en unknown
- 2017-05-17 WO PCT/EP2017/061865 patent/WO2017198726A1/en not_active Ceased
-
2018
- 2018-11-14 MX MX2024005757A patent/MX2024005757A/es unknown
-
2022
- 2022-05-23 US US17/751,319 patent/US20220289797A1/en active Pending
- 2022-10-06 JP JP2022161464A patent/JP7547433B2/ja active Active
-
2023
- 2023-12-18 AU AU2023285703A patent/AU2023285703A1/en active Pending
-
2024
- 2024-08-28 JP JP2024146333A patent/JP2024170461A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL262963B1 (en) | 2024-09-01 |
| MX2024005757A (es) | 2024-05-24 |
| JP2023012463A (ja) | 2023-01-25 |
| KR20240095333A (ko) | 2024-06-25 |
| IL262963B2 (en) | 2025-01-01 |
| MX2018013956A (es) | 2019-07-04 |
| IL314272A (en) | 2024-09-01 |
| NZ788311A (en) | 2025-11-28 |
| WO2017198726A1 (en) | 2017-11-23 |
| CA3023599A1 (en) | 2017-11-23 |
| JP7254018B2 (ja) | 2023-04-07 |
| US20220289797A1 (en) | 2022-09-15 |
| CN109804074B (zh) | 2023-10-10 |
| AU2023285703A1 (en) | 2024-01-18 |
| CN117486979A (zh) | 2024-02-02 |
| KR20190016032A (ko) | 2019-02-15 |
| CN109804074A (zh) | 2019-05-24 |
| IL262963A (en) | 2018-12-31 |
| NZ748120A (en) | 2025-08-29 |
| EP3458593A1 (en) | 2019-03-27 |
| EA201892648A1 (ru) | 2019-06-28 |
| JP2019516410A (ja) | 2019-06-20 |
| JP2024170461A (ja) | 2024-12-10 |
| AU2017266738B2 (en) | 2023-10-12 |
| SG11201810048VA (en) | 2018-12-28 |
| JP7547433B2 (ja) | 2024-09-09 |
| KR102671785B1 (ko) | 2024-06-04 |
| US20190135875A1 (en) | 2019-05-09 |
| AU2017266738A1 (en) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018073794A2 (pt) | segmento genômico, cdna, vetor, célula hospedeira, partícula, método de produção de um segmento genômico, método de geração da partícula, vacina, composição farmacêutica | |
| BR212016030926U2 (pt) | conjugados de alvo e partículas e formulações dos mesmos | |
| BR112018068748A2 (pt) | composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto | |
| CN111344398A (zh) | 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 | |
| MX392028B (es) | Vacunas para el tratamiento y prevención del cáncer. | |
| BR112015021414A2 (pt) | vírus da doença newcastle e seus usos | |
| CY1121874T1 (el) | Παραγωγα μονο- ή διυποκατεστημενου ινδολιου ως αναστολεις του αναδιπλασιασμου του ιου του δαγκειου πυρετου | |
| BR112015017966A2 (pt) | composições imunogênicas compreendendo vírus silificado e métodos de uso | |
| BR112018077021A2 (pt) | terapias de combinação | |
| MY188734A (en) | Use of alphavirus in preparation of antitumor drugs | |
| EA201791903A1 (ru) | β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ | |
| BR112016026721A2 (pt) | vacinas com base em vesículas do tipo vírus (vlvs) para prevenir ou tratar infecção por vírus da hepatite b (hbv) crônica | |
| BR112015020139A2 (pt) | compostos terapêuticos e usos dos mesmos | |
| BR112016025764A2 (pt) | vacina de peptídeo compreendendo peptídeo ras mutante e agente quimioterapêutico | |
| PH12016502500A1 (en) | Influenza virus vaccines and uses thereof | |
| BR112017013999A2 (pt) | ?composição derivada de uma bifidobactéria? | |
| MX2019008105A (es) | Virus. | |
| WO2015054678A3 (en) | Human papilloma virus therapeutic vaccine | |
| BR112015023793A2 (pt) | composições e métodos de terapias para indução de tolerância imune a substituição do fator vii em indivíduos com hemofilia a | |
| BR112015015045A8 (pt) | partículas derivadas de vírus não replicante e respectivos usos. | |
| BR112016017242A2 (pt) | Vetores lentivirais para gerar respostas imunes contra o vírus linfotrópico-t humano do tipo 1 | |
| MX2017002949A (es) | Arbovirus recodificado y vacunas. | |
| BR112018013967A2 (pt) | vacinas contra o câncer | |
| BR112017009193A2 (pt) | método de tratamento de uma doença infecciosa, câncer, ou doença mieloproliferativa em um indivíduo; método de tratamento de uma doença mieloproliferativa em um indivíduo; e; interferon tipo i | |
| BR112017007435A2 (pt) | formulações contendo tiotrópio, aminoácido e ácido e seus métodos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122025019601-0 PROTOCOLO 870250082758 EM 15/09/2025 11:55. |